Venous thromboembolism prophylaxis for hospitalized medical patients, current status and strategies to improve

Annals of Thoracic Medicine

Volumn 5, Issue 4, 2010, Pages 195-200

  Abdel Razeq, Hikmat ^a  

^a KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

Deep vein thrombosis; heparin; low molecular weight heparin; pulmonary embolism; thromboprophylaxis

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PLACEBO;

BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE POLICY; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG EMBOLISM; MEDICAL AUDIT; PROPHYLAXIS; REVIEW; RISK FACTOR; STROKE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 77957004458     PISSN: 18171737     EISSN: 19983557     Source Type: Journal    
DOI: 10.4103/1817-1737.69104     Document Type: Review

References (41)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938
2. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861-866 (Pubitemid 24135768)
3. Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, Mohr DN, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001;76:1102-1110
4. Tapson VF. Prophylaxis strategies for patients with acute venous thromboembolism. Am J Manag Care 2001;7:S524-31; discussion S531-4.
5. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7. (Pubitemid 126505333)
6. Gillies TE, Ruckley CV, Nixon SJ. Still missing the boat with fatal pulmonary embolism. Br J Surg 1996;83:1394-1395
7. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based, cohort study. Arch Intern Med 1999;159:445-453
8. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-593
9. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Worcester DVT Study. Arch Intern Med 1991;151:933-938
10. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: Analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-968 (Pubitemid 38581515)
11. Heit JA. Venous thromboembolism: Disease burden, outcomes and risk factors. J Thromb Haemost 2005;3:1611-1617 (Pubitemid 41716546)
12. Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998;128:467-477 (Pubitemid 28128708)
13. Devor M, Barrett-Connor E, Renvall M, Feigal D Jr, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992;92:275-282
14. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 1986;16:159-164 (Pubitemid 16088181)
15. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-117 (Pubitemid 11032070)
16. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
17. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 1997;50:609-610 (Pubitemid 27359522)
18. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-450
19. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patient. Circulation 2004;110:874-879 (Pubitemid 39096017)
20. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-19 (Pubitemid 30045469)
21. Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93:259-262 (Pubitemid 38058748)
22. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, Turpie AG, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007;119:145-155 (Pubitemid 44810862)
23. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936-945
24. Agu O, Hamilton G, Baker D. Graduated compression stockings in the prevention of venous thromboembolism. Br J Surg 1999;86:992-1004. (Pubitemid 29387063)
25. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000;3:CD001484.
26. McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J 2006;4:17. (Pubitemid 44734060)
27. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/ safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996;26:49-56. (Pubitemid 26098865)
28. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-621 (Pubitemid 36403489)
29. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, et al. PREVAIL investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): An open-label randomised comparison. Lancet 2007;369:1347-1355 (Pubitemid 46621092)
30. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S. (Pubitemid 351894916)
31. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial. Ann Intern Med 2010;153:8-18.
32. Turpie AG. Extended duration of thromboprophylaxis in acutely ill medical patients: Optimizing therapy? J Thromb Haemost 2007;5:5-11. (Pubitemid 44921060)
33. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/Org 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995;74:1474-1477
34. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 2004;140:867-873 (Pubitemid 38685267)
35. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-1702 (Pubitemid 37315006)
36. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ 2006;332:325-329 (Pubitemid 43253745)
37. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study. Lancet 2008;371:387-394 (Pubitemid 351173321)
38. National Quality Forum (NQF) at (NQF). Available from: http:// www.qualityforum.org/Measures-List.aspx#k=THROMBOSIS [last cited on 2010 Jan 26].
39. The Joint Commission Manual for Future Performance Improvement Measures. Available from: http://www.jointcommission.org/ PerformanceMeasurement/ PerformanceMeasurement/VTE.htm [last cited on 2010 January 20].
40. Maynard G, Stein J. Designing and implementing effective venous thromboembolism prevention protocols: Lessons from collaborative efforts. J Thromb Thrombolysis 2010;29:159-166
41. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005;352:969-977 (Pubitemid 40349499)